AmerisourceBergen establishes Clinical Trial Navigator tool to increase access to research opportunities

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

AmerisourceBergen launched Clinical Trial Navigator, a solution suite that supports biopharmaceutical clinical trial recruitment within community-based specialty practices. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

When Marsha B. Henderson, former FDA Associate Commissioner of Women’s Health (1998-2019), sat down for an oral history interview upon her retirement from the agency, she could not have foreseen becoming party to a government digital purge 7 years later.  Over the past week, the Trump administration has been busy at work deleting government webpages...

Patients with metastatic colorectal cancer harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies Braftovi(encorafenib) and Erbitux(cetuximab) plus a mFOLFOX6 chemotherapy regimen, according to results from the phase III BREAKWATER trial led by researchers at the University of Texas MD Anderson Cancer Center.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login